Lai Kuan Leong

Lai Kuan Leong

Auto-generated profile, based on publicly available information

Lai Kuan Leong

Ministry Of Health Malaysia, Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
LLLai Kuan Leong
Lai Kuan Leong
BCBui Khiong Chung
Bui Khiong Chung
CTChen Ting Tan
Chen Ting Tan

29 December 2023 in International Journal of Cardiology
Verified
Journal Article
Open access
HKH.K. Khor
H.K. Khor
MNM.N. Nadia
M.N. Nadia
YLY.X. Liew
Y.X. Liew
SKS.S. Koh
S.S. Koh
AFA.Y.Y. Fong
A.Y.Y. Fong
TOT.K. Ong
T.K. Ong

14 September 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
CBChenghong Bao
Chenghong Bao
LLLai Kuan Leong
Lai Kuan Leong
YJYuanhao Jin
Yuanhao Jin
QWQian Wang
Qian Wang
THTianhua Hou
Tianhua Hou
LWLingmin Wu
Lingmin Wu

24 March 2026 in Journal of Asian Pacific Society of Cardiology
Verified
Journal Article
Open access
LLLai Kuan Leong
Lai Kuan Leong
KCKit Hou Chiang
Kit Hou Chiang
KKKenneth Kay Leong Khoo
Kenneth Kay Leong Khoo
HLHwei Sung Ling
Hwei Sung Ling
Asri SaidAsri Said
Asri Said
KKKeng Tat Koh
Keng Tat Koh
Background: This study sought to examine the efficacy and safety of cardioneuroablation (CNA) and pacemaker (PM) therapy in patients with functional bradycardia. Methods: We included 14 patients with functional bradycardia who underwent CNA or PM in our centre in Malaysia from 2019–2024 (CNA n=8; PM n=6). The primary efficacy endpoint was time to first syncope recurrence, switching from CNA to PM or from PM to CNA. The secondary efficacy endpoint was a composite of time to first syncope, presyncope or prodrome recurrence. The safety endpoint of the study was complications related to CNA or PM. Results: The median age of the patients for the CNA and PM groups was 46.5 and 37.5 years old (p=0.27), respectively. The median number of syncopal events before CNA or PM therapy was 2.2 and 2.5 (p=0.60), respectively. There were 62.5% of patients in the CNA group and 83.3% of patients in the PM group who had sustained traumatic injury post-syncope. At 1 year, the primary efficacy endpoint was met in one patient in the CNA group and one patient in the PM group (p=0.88). Recurrent syncope occurred in one patient in the PM group and no patients in the CNA group (p=0.25). The safety endpoint occurred in one patient in the PM group and none in the patients in the CNA group (p=0.25). Conclusion: CNA and PM appeared to be effective and safe for functional bradycardia patients. Larger studies with longer follow-ups are needed to establish long-term outcomes.